Disease trends
Trial starts and publications for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, and systemic lupus erythematosus. Arthritis prevalence comes from CDC Chronic Disease Indicators. IBD does not have a matching CDC dataset, so the literature and the trial registry are the trend.
FAERS data as of 2026-07-30. How these numbers are made
Publications per year
PubMed records matching each condition’s MeSH term. The current calendar year is year-to-date.
| Year | Rheumatoid arthritis | Crohn's disease | Ulcerative colitis | Psoriasis | Systemic lupus erythematosus |
|---|---|---|---|---|---|
| 2016 | 0 | 1,649 | 1,368 | 1,955 | 2,043 |
| 2017 | 0 | 1,636 | 1,344 | 2,215 | 2,053 |
| 2018 | 0 | 1,527 | 1,332 | 2,268 | 2,113 |
| 2019 | 0 | 1,672 | 1,492 | 2,375 | 2,195 |
| 2020 | 0 | 1,852 | 1,894 | 2,811 | 2,370 |
| 2021 | 0 | 1,812 | 1,993 | 2,661 | 2,564 |
| 2022 | 0 | 1,873 | 2,238 | 2,648 | 2,509 |
| 2023 | 0 | 1,826 | 2,247 | 2,459 | 2,369 |
| 2024 | 0 | 1,870 | 2,328 | 2,524 | 2,289 |
| 2025 | 0 | 1,743 | 2,389 | 2,187 | 2,213 |
| 2026 | 0 | 1,199 | 1,613 | 1,443 | 1,710 |
Trials started per year
ClinicalTrials.gov studies whose start date falls in the year. This is not a count of status changes.
| Year | Rheumatoid arthritis | Crohn's disease | Ulcerative colitis | Psoriasis | Systemic lupus erythematosus |
|---|---|---|---|---|---|
| 2016 | 193 | 86 | 98 | 130 | 37 |
| 2017 | 158 | 104 | 91 | 131 | 57 |
| 2018 | 148 | 101 | 104 | 133 | 63 |
| 2019 | 147 | 112 | 115 | 160 | 56 |
| 2020 | 163 | 114 | 98 | 126 | 60 |
| 2021 | 182 | 124 | 111 | 160 | 85 |
| 2022 | 151 | 129 | 119 | 140 | 99 |
| 2023 | 166 | 106 | 113 | 136 | 100 |
| 2024 | 159 | 132 | 136 | 121 | 145 |
| 2025 | 179 | 144 | 146 | 155 | 152 |
| 2026 | 156 | 135 | 156 | 123 | 163 |
Weekly spike screen
The latest complete week is compared with the weeks before it. A spike needs a z-score of at least 2 and a count at least 1.5 times the baseline mean, with four or more earlier weeks. FDA notices often lack that much history in a single RSS pull.
| Series | Topic | Week | Count | Baseline | Latest week |
|---|---|---|---|---|---|
| publications | Rheumatoid arthritis | 2026-W41 | 0 | 0.0 | Within baseline |
| publications | Crohn's disease | 2026-W41 | 8 | 30.6 | Within baseline |
| publications | Ulcerative colitis | 2026-W41 | 9 | 42.8 | Within baseline |
| publications | Psoriasis | 2026-W41 | 6 | 37.9 | Within baseline |
| publications | Systemic lupus erythematosus | 2026-W41 | 4 | 49.5 | Within baseline |
| trials | Rheumatoid arthritis | 2026-W41 | 1 | 3.5 | Within baseline |
| trials | Crohn's disease | 2026-W41 | 1 | 3.3 | Within baseline |
| trials | Ulcerative colitis | 2026-W41 | 2 | 3.8 | Within baseline |
| trials | Psoriasis | 2026-W41 | 1 | 2.6 | Within baseline |
| trials | Systemic lupus erythematosus | 2026-W41 | 0 | 3.8 | Within baseline |
| alerts | FDA notices | 2026-W42 | 24 | 4.0 | Spike |
Earlier weeks that cleared the same rule: Ulcerative colitis 2026-W36 (98); Psoriasis 2026-W36 (104); Systemic lupus erythematosus 2026-W36 (101); Systemic lupus erythematosus 2026-W40 (101); Rheumatoid arthritis 2026-W36 (13); Rheumatoid arthritis 2026-W40 (13); Crohn's disease 2026-W36 (10); Ulcerative colitis 2026-W40 (9); Psoriasis 2026-W36 (9); Systemic lupus erythematosus 2026-W36 (12); Systemic lupus erythematosus 2026-W40 (11).
Arthritis among US adults
CDC Chronic Disease Indicators, dataset hksd-2xuw, crude prevalence among US adults, BRFSS.
| Year | Percent |
|---|---|
| 2019 | 25.0 |
| 2020 | 24.2 |
| 2021 | 25.2 |
| 2022 | 26.6 |
| 2023 | 25.4 |
data.cdc.gov has no IBD surveillance dataset comparable to Chronic Disease Indicators. Dataset hksd-2xuw includes arthritis. Crohn's disease and ulcerative colitis trends in this monitor are ClinicalTrials.gov start counts and PubMed publication counts.
A data.cdc.gov catalog search for inflammatory bowel disease did not return a surveillance table comparable to Chronic Disease Indicators. IBD trends on this dashboard use ClinicalTrials.gov and PubMed.
Recent publications
- Rapid fecal lipidome profiling in inflammatory bowel disease: A novel approach for exploratory disease molecular characterization and therapeutic monitoring
- Human gut flagellome profiling using FlaPro reveals TLR5-related phenotype-specific alterations in IBD
- High thrombin activity associated with crohn's disease induces microbiota pathogenicity contributing to mucosal inflammation
- Responses of intestinal organoids to infection by Mycobacterium avium resemble symptoms observed in Crohn's disease
- Miniature bioreactor arrays for modeling functional and structural dysbiosis in inflammatory bowel disease
- Leveraging electronic health records for subtype-dependent directionality in depression and gastrointestinal disease: a retrospective cohort study
- Integrated DIA proteomics of tissue and exudate reveals screening markers for early detection of ulcerative colitis and colorectal cancer
- Reduced fecal GP2 levels in ulcerative colitis associate with inflammatory activity and microbial composition
Titles and links only. Abstracts are not shown. NCBI disclaimer.
Recently updated trials
- Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
NCT06293365ACTIVE_NOT_RECRUITINGPHASE2
- Pain Phenotyping of Rheumatic Diseases - An Observational Study
NCT07829497NOT_YET_RECRUITING
- A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
NCT07245992RECRUITINGPHASE1
- A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
NCT07873931NOT_YET_RECRUITINGPHASE1
- Phase 1b/2 Study of IV Sarilumab in Adult With RA
NCT07704580RECRUITINGPHASE1, PHASE2
- A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07607964RECRUITINGPHASE1
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809RECRUITINGPHASE3
- The Pathogenesis and Natural History of Sjogren's Disease
NCT01425892RECRUITING